PA8784401A1 - Derivado de 17b-ciano-19-nor-androst-4-eno, su uso y medicamento que lo contiene - Google Patents

Derivado de 17b-ciano-19-nor-androst-4-eno, su uso y medicamento que lo contiene

Info

Publication number
PA8784401A1
PA8784401A1 PA20088784401A PA8784401A PA8784401A1 PA 8784401 A1 PA8784401 A1 PA 8784401A1 PA 20088784401 A PA20088784401 A PA 20088784401A PA 8784401 A PA8784401 A PA 8784401A PA 8784401 A1 PA8784401 A1 PA 8784401A1
Authority
PA
Panama
Prior art keywords
hydrogen
group
ciano
androst
eno
Prior art date
Application number
PA20088784401A
Other languages
English (en)
Inventor
Ring Sven
Klar Ulrich
Bohlmann Rolf
Muhn Hans-Peter
Prelle Katja
Borden Steffen
Kuhnke Joachim
Huebner Jan
Menges Frederik
Frenzel Thomas
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PA8784401A1 publication Critical patent/PA8784401A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J53/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002Carbocyclic rings fused
    • C07J53/0043 membered carbocyclic rings
    • C07J53/0083 membered carbocyclic rings in position 15/16
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34Gestagens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J53/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002Carbocyclic rings fused
    • C07J53/0043 membered carbocyclic rings
    • C07J53/0073 membered carbocyclic rings in position 6-7

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Toxicology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LOS DERIVADOS DE 17ß-CIANO -19-NOR-ANDROST-4-ENO DE LA PRESENTE INVENCION PRESENTAN ACTIVIDAD GESTAGENA. TIENEN LA FORMULA QUIMICA GENERAL 1, EN LA CUAL Z SE SELECCIONA DEL GRUPO QUE COMPRENDE O, DOS ATOMOS DE HIDROGENO, NOR Y NNHSO2R, DONDE R ES HIDROGENO O C1-C4-ALQUILO, R4 ES HIDROGENO O HALOGENO, ADEMAS O BIEN: R6A, R6B JUNTOS FORMAN METILENO O 1, 2-ETANODIILO O R6A ES HIDROGENO Y R6B SE SELECCIONA DEL GRUPO QUE COMPRENDE HIDROGENO, METILO E HIDROXIMETILENO, Y R7 SE SELECCIONA DEL GRUPO QUE COMPRENDE HIDROGENO, C1-C4-ALQUILO, C2-C3-ALQUENILO Y CICLOPROPILO, O: R6A ES HIDROGENO Y R6B Y R7 JUNTOS FORMAN METILENO O SE OMITEN POR FORMACION DE UN ENLACE DOBLE ENTRE C6 Y C7., R9, R10 SON HIDROGENO O SE OMITEN POR FORMACION DE UN ENLACE DOBLE ENTRE C9 Y C10, R15, R16 SON HIDROGENO O JUNTOS FORMAN METILENO, R17 SE SELECCIONA DEL GRUPO QUE COMPRENDE HIDROGENO, C1-C4-ALQUILO Y ALILO, DONDE AL MENOS UNO DE LOS SUSTITUYENTES R4, R6A, R6B, R7, R15, R16 Y R17 NO ES HIDROGENO O R6B Y R7 SE OMITEN POR FORMACION DE UN ENLACE DOBLE ENTRE C6 Y C7, Y SUS SOLVATOS, HIDRATOS, ESTEREOISOMEROS, DIASTEREOMEROS, ENANTIOMEROS Y SALES.
PA20088784401A 2007-06-12 2008-06-11 Derivado de 17b-ciano-19-nor-androst-4-eno, su uso y medicamento que lo contiene PA8784401A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007027637A DE102007027637A1 (de) 2007-06-12 2007-06-12 17ß-Cyano-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel

Publications (1)

Publication Number Publication Date
PA8784401A1 true PA8784401A1 (es) 2009-01-23

Family

ID=39986163

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20088784401A PA8784401A1 (es) 2007-06-12 2008-06-11 Derivado de 17b-ciano-19-nor-androst-4-eno, su uso y medicamento que lo contiene

Country Status (20)

Country Link
US (1) US8207150B2 (es)
EP (1) EP2170925B1 (es)
JP (1) JP2010529153A (es)
KR (1) KR20100028554A (es)
CN (1) CN101679478A (es)
AR (1) AR066971A1 (es)
AU (1) AU2008261278A1 (es)
BR (1) BRPI0813937A2 (es)
CA (1) CA2690959A1 (es)
DE (1) DE102007027637A1 (es)
ES (1) ES2397996T3 (es)
IL (1) IL202359A0 (es)
MX (1) MX2009013629A (es)
PA (1) PA8784401A1 (es)
PE (1) PE20090822A1 (es)
RU (1) RU2010100331A (es)
TW (1) TW200909444A (es)
UY (1) UY31146A1 (es)
WO (1) WO2008151746A2 (es)
ZA (1) ZA201000187B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007027637A1 (de) 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17ß-Cyano-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007027635A1 (de) * 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17ß-Cyano-19-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
WO2010066355A1 (de) * 2008-12-12 2010-06-17 Bayer Schering Pharma Aktiengesellschaft VERWENDUNG VON 17β- CYANO-19-NOR-ANDROST-4-EN-DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS IN DEPOT-FORM ZUR PARENTERALEN ANWENDUNG SOWIE DEPOT-ARZNEIMITTEL ENTHALTEND 17β-CYANO-19-NOR-ANDROST-4-EN-DERIVATE ZUR PARENTERALEN ANWENDUNG
WO2012059594A1 (en) 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity
CN104530165A (zh) * 2014-12-10 2015-04-22 浙江仙琚制药股份有限公司 制备4,9-双烯物的方法
CN105085596A (zh) * 2015-08-18 2015-11-25 湖北竹溪人福药业有限责任公司 一种羧酸黄体酮的制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3043833A (en) * 1961-07-14 1962-07-10 Ormonoterapia Richter Spa 17-cyanohydrin of 19-nor androstenedione and 3-derivatives thereof
DE1183500B (de) 1962-10-12 1964-12-17 Schering Ag Verfahren zur Herstellung von alpha, beta-Methylenketonen der Steroidreihe
US3579509A (en) * 1965-06-21 1971-05-18 Smith Kline French Lab Process and 6-beta-substituted ethyl intermediates for preparing 6,6-ethylene-3-keto-delta**4 steroids
GB1089945A (en) * 1965-09-23 1967-11-08 British Drug Houses Ltd Steroidal-6-spirocyclopropyl-4-en-3-ones
CH538462A (de) * 1970-10-07 1973-06-30 Ciba Geigy Ag Ein neues Verfahren zur Herstellung von 6a-Methyl-19-nor-pregnenen
US3705179A (en) 1971-03-15 1972-12-05 American Home Prod Antiandrogenic steroids
FR2139708B1 (es) * 1971-06-01 1974-08-23 Roussel Uclaf
BE795241A (fr) 1972-02-11 1973-08-09 Schering Ag 15alpha, 16alpha-methylene-4-oestren-17beta-ols-methylenz-4-oestren-17beta-ols et leur procede de preparation
DE2456068A1 (de) 1974-11-23 1976-08-12 Schering Ag Verfahren zur herstellung von oestren3,17-dion-derivaten
NL7701384A (nl) 1977-02-10 1978-08-14 Akzo Nv Werkwijze voor het bereiden van nieuwe steroiden van de oestraanreeks.
DE2922500A1 (de) 1979-05-31 1980-12-04 Schering Ag 6 beta .7 beta
US4252800A (en) * 1979-10-05 1981-02-24 United States Of America 7α-methylnorethindrone enanthate and its use in long term suppression of fertility in female mammals
US4512986A (en) * 1983-07-26 1985-04-23 Research Triangle Institute Progrestationally active steroids
US4544554A (en) * 1983-09-26 1985-10-01 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
DE3402329A1 (de) 1984-01-20 1985-08-01 Schering AG, 1000 Berlin und 4709 Bergkamen 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
DD281393A5 (de) * 1984-12-10 1990-08-08 Jenapharm Veb Verfahren zur herstellung von steroid-c-17 beta-carbonitrilen
DD281394A5 (de) * 1984-12-10 1990-08-08 Jenapharm Veb Verfahren zur herstellung von steroid-c-17 alpha-carbonitrilen
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
EP0785211A1 (en) * 1996-01-22 1997-07-23 Laboratoire Theramex New substituted 19-nor-pregnane derivatives
DE19651000A1 (de) 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
DE102004063864A1 (de) 2004-12-30 2006-07-13 Schering Ag 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
DE102007027637A1 (de) 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17ß-Cyano-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel

Also Published As

Publication number Publication date
KR20100028554A (ko) 2010-03-12
US8207150B2 (en) 2012-06-26
JP2010529153A (ja) 2010-08-26
EP2170925B1 (de) 2012-10-24
EP2170925A2 (de) 2010-04-07
ES2397996T3 (es) 2013-03-13
US20090048217A1 (en) 2009-02-19
CA2690959A1 (en) 2008-12-18
BRPI0813937A2 (pt) 2014-12-30
AU2008261278A1 (en) 2008-12-18
MX2009013629A (es) 2010-01-20
PE20090822A1 (es) 2009-07-25
RU2010100331A (ru) 2011-07-20
WO2008151746A2 (de) 2008-12-18
WO2008151746A3 (de) 2009-03-12
DE102007027637A1 (de) 2008-12-18
UY31146A1 (es) 2009-01-30
TW200909444A (en) 2009-03-01
ZA201000187B (en) 2011-03-30
IL202359A0 (en) 2010-06-30
CN101679478A (zh) 2010-03-24
AR066971A1 (es) 2009-09-23

Similar Documents

Publication Publication Date Title
PA8784201A1 (es) Derivado de 17b-ciano-18a-homo-19-nor-androst-4-eno, su uso y medicamento que lo contiene
PA8784401A1 (es) Derivado de 17b-ciano-19-nor-androst-4-eno, su uso y medicamento que lo contiene
DOP2006000076A (es) Derivados de ciclopentapiridina y tetrahidroquinolina
CY1113757T1 (el) Παραγωγα πιπεριδινης και πιπεραζινης για τη θεραπεια ογκων
CU20100021A7 (es) Derivado de oxopirazina y herbicida
CY1109729T1 (el) Τερφαινυλ παραγωγα για θεραπεια της νοσου του alzheimer
MA31580B1 (fr) Derives de bicyclolactames substitués
ECSP12012161A (es) Compuestos en calidad de antagonistas de Bradiquinina-b1
CY1121984T1 (el) Μη-ορμονικοι στεροειδεις ρυθμιστες toy nf-kb για θεραπεια ασθενειας
GT200600155A (es) Compuestos utiles en terapia
DOP2011000281A (es) Derivados de benzofurano
ATE467632T1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
CY1108366T1 (el) Βενζοσουλφονικο αλας της 7-(2-(4-(3-τριφθορομεθυλ-φαινυλ-1,2,3,6-τετραϋδρο-πυριδ-1-υλ)αιθυλ)ισοκινολινης, η παρασκευη του και η χρηση του στη φαρμακευτικη αγωγη
CO6531479A2 (es) Derivados de espirolactama y uso de los mismos
AR029706A1 (es) Derivados de tetrazol
AR058377A1 (es) Derivados de pirroliltriazina, procedimientos para su obtencion y formulacion cosmetica y farmaceutica
CO5570696A2 (es) 1-amino-alquilciclohexanos insaturados como antagonistas de los receptores nmda, 5ht3 y nicotinico neuronal
AR064306A1 (es) Antagonistas del receptor de angiotensina ii
PA8810701A1 (es) Derivados de 19-nor-esteroide que tiene un grupo 15a,16a-metileno y un anillo de 17,17-espirolactona saturado, su uso y medicamentos que los comprenden
ATE527228T1 (de) Verfahren zur herstellung von beta-santalol und derivaten davon
CY1107193T1 (el) Παραγωγα πιπεραζινης και η χρηση τους ως αναστολεων της επανασυλληψης της σεροτονινης ή ως ανταγωνιστων της νευροκινινης
AR057748A1 (es) Derivados de 2,3 dihidroindol. composiciones farmaceuticas
AR069963A1 (es) Derivado 15, 16-metilen-17- (1'-propenil)-17-3'-oxidoestra-4-en-3-ona, su uso y medicamento que lo contiene
TW200745187A (en) Protecting agent
PA8809901A1 (es) Derivado de y-lactona de esteroide de ácido 15, 16-metilen-17-hidroxi-19-nor-21-carboxílico, su uso y medicamento que lo contiene